Jerry McLaughlin, CEO of Life Biosciences, and John Maslowski, newly appointed CEO of Forge Biologics, delve into groundbreaking topics in biotech. They discuss advancements in partial epigenetic reprogramming therapies and their collaboration on clinical trials. The conversation also highlights strategic growth and leadership changes at Forge after its acquisition. Insights into the thriving biotech environment in Columbus are shared, emphasizing the importance of trust and communication in successful partnerships within the sector.